Global cardiovascular protection in chronic kidney disease

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Cardiovascular disease (CVD) and renal disorders share a close relationship.
• Patients with chronic kidney disease (CKD) often receive suboptimal cardiorenal protection.
• Standard therapies like ACE inhibitors, ARBs, and MRAs risk hyperkalemia, limiting their use in CKD.

Purpose of the Study:

• To review available treatments for adequate cardiorenal protection in CKD patients.
• To discuss strategies for managing hyperkalemia in CKD patients undergoing cardiorenal protection.
• To explore new compounds and dosing strategies for improved long-term prognosis in CKD.

Main Methods:

• Literature review of current and emerging therapies for cardiorenal protection.
• Discussion of drug classes including beta-blockers, potassium binders, nonsteroidal MRAs, and statins.
• Analysis of new compounds and updated dosing recommendations for CKD management.

Main Results:

• Incomplete renin-angiotensin-aldosterone system blockade is common in CKD due to hyperkalemia concerns.
• Agents like beta-blockers, potassium binders, and nonsteroidal MRAs offer potential for cardiorenal protection.
• Statins and novel compounds show promise, but require further investigation for optimal CKD treatment.

Conclusions:

• Optimizing cardiorenal protection in CKD requires careful management of hyperkalemia.
• Further research on new agents and dosing is crucial to improve cardiovascular and renal outcomes in CKD.
• A comprehensive approach combining existing and novel therapies is needed for better long-term prognosis.